H. pylori Treatment Recommendations
The preferred treatment for H. pylori infection is a 14-day bismuth quadruple therapy regimen containing a proton pump inhibitor, bismuth subsalicylate, tetracycline, and metronidazole, which has an eradication rate of 85%. 1
First-Line Treatment Options
Preferred Regimen
- Bismuth Quadruple Therapy (14 days):
- Proton pump inhibitor (PPI)
- Bismuth subsalicylate
- Tetracycline
- Metronidazole
- Eradication rate: 85% 1
Alternative Regimens
Concomitant Non-Bismuth Quadruple Therapy (14 days):
- PPI
- Amoxicillin
- Metronidazole
- Clarithromycin
- Eradication rate: 80% 1
Standard Triple Therapy (14 days):
- PPI
- Clarithromycin
- Amoxicillin
- Eradication rate: 85% (only recommended in areas with low clarithromycin resistance <20%) 1
Dual Therapy for H. pylori:
- 1 gram amoxicillin three times daily
- 30 mg lansoprazole three times daily
- Duration: 14 days 2
Treatment Administration
- Medications should be taken at the start of a meal to minimize gastrointestinal intolerance 2
- All H. pylori eradication regimens should now be given for 14 days due to increasing treatment failure with shorter durations 1, 3
- For triple therapy specifically, the FDA-approved dosing is 1 gram amoxicillin, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily for 14 days 2
Testing Before and After Treatment
Before initiating treatment:
After treatment:
- Perform follow-up test at least 4 weeks after completion of treatment
- Use urea breath test or monoclonal stool antigen test (sensitivity 90%, specificity 95%) 1
Management of Treatment Failure
- If first-line therapy fails, use a different regimen than the initial treatment 1
- After two treatment failures, obtain antimicrobial susceptibility testing to guide further treatment 1
- For treatment-experienced patients with persistent H. pylori infection, "optimized" bismuth quadruple therapy for 14 days is preferred for those who have not been treated with optimized bismuth quadruple therapy previously 1, 3
- Levofloxacin-based therapy can be considered as a rescue treatment 1, 4
- Rifabutin regimens should be restricted to patients who have failed to respond to at least 3 prior options 3
Special Considerations
Patient Referral
- Patients over 45 years with severe symptoms or any patients with alarm symptoms (anemia, weight loss, dysphagia, palpable mass, malabsorption) should be referred for endoscopy before treatment 1
- Younger patients (<45 years) without alarm symptoms can be managed in primary care 1
Ulcer Management
- For gastric ulcers, PPI therapy should be continued until complete healing is achieved 1
- For duodenal ulcers, PPI therapy should be continued until bacterial eradication is confirmed 1
- Patients with bleeding ulcers should start treatment when oral feeding is resumed 1
Antibiotic Resistance
- In areas with high clarithromycin resistance, bismuth-containing quadruple therapy is the preferred first-line treatment 1, 5
- Antibiotic resistance is a major cause of treatment failure, with clarithromycin resistance being particularly problematic 5, 6
Penicillin Allergy
- Consider penicillin allergy testing in patients with a history of penicillin allergy but without anaphylaxis, to potentially enable the use of amoxicillin-containing regimens 1
- For patients with confirmed penicillin allergy, bismuth quadruple therapy is a suitable alternative as it does not contain amoxicillin 7
Common Pitfalls and Caveats
- Inadequate treatment duration: Ensure full 14-day treatment course to maximize eradication rates 1, 3
- Ignoring antibiotic resistance patterns: Consider local resistance patterns when selecting therapy 1, 5
- Poor patient compliance: Educate patients about the importance of completing the full course of treatment despite potential side effects 6
- Failure to confirm eradication: Always perform post-treatment testing to confirm successful eradication 1
- Common side effects include diarrhea, skin rash, vomiting, nausea, metallic taste, and muscle and joint pains 1
- Renal impairment: Patients with severe renal impairment (GFR <30 mL/min) should NOT receive the 875 mg dose of amoxicillin 2